Skip to main content

Quest Diagnostics Value Stock - Dividend - Research Selection

Quest diagnostics

ISIN: US74834L1008 , WKN: 904533

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company\'s Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. Its Diagnostic Solutions segment offers risk assessment services for the life insurance industry; and health information technology solutions for healthcare organizations and clinicians. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Barclays Maintains Quest Diagnostics (DGX) Equal-Weight Recommendation

2025-10-03

Quest Diagnostics Joins Forces With Epic to Improve Laboratory Testing

2025-10-01
DGX teams up with Epic on Project Nova to streamline lab testing, boost efficiency, and enhance patient and provider experiences.

Oura launches Ring 4 Ceramic collection, new charging case, and a ‘health panel’ feature

2025-10-01
The new Oura Ring 4 Ceramic is made from zirconia ceramic, which the company says allows for durability and lightweight comfort.

DGX's Haystack Oncology Teams Up With Rutgers Cancer Institute

2025-09-30
Quest Diagnostics' Haystack Oncology joins Rutgers Cancer Institute to study how its ctDNA MRD test can guide therapy for stage II/III lung cancer.

Whoop opens blood-testing service to what it says is a 350,000-person waitlist

2025-09-30
Whoop Advanced Labs marries subscription blood tests with its fitness device monitoring for tech-powered wellness advice.

Quest Diagnostics Incorporated (DGX) Presents at Jefferies 2025 Healthcare Services Conference Transcript

2025-09-29
Quest Diagnostics Incorporated (NYSE:DGX) Jefferies 2025 Healthcare Services Conference September 29, 2025 4:35 PM EDTCompany ParticipantsSam Samad -...

Why Guardant Health (GH) Stock Is Trading Up Today

2025-09-29
Shares of diagnostics company Guardant Health (NASDAQ:GH) jumped 1.6% in the morning session after the U.S. Food and Drug Administration (FDA) approved its Guardant360® CDx blood test as a companion diagnostic for Eli Lilly's new advanced breast cancer treatment, Inluriyo™.

How Quest Diagnostics’ 25% Rally and AI Push Are Shaping Its 2025 Valuation

2025-09-27
If you are grappling with what to do next about Quest Diagnostics stock, you are certainly not alone. The company’s performance has been catching some attention lately and for good reason. Quest Diagnostics is fresh off a period of steady share price gains, with the stock up 2.9% over the last week and showing a healthy 5.1% rise over the past month. Step back a bit further, and the story looks even more impressive: a year-to-date gain of 25.2% and an 83.2% return over five years highlight...

Dividend Champion, Contender, And Challenger Highlights: Week Of September 28

2025-09-26
Read the latest dividend updates for Dividend Champions, Contenders, and Challengers. Track changes, ex-dividend, and pay dates.

Oxford Partners Expands into Healthcare Real Estate with Appointment of Nelson Udstuen as President of Healthcare Division

2025-09-26
Oxford Partners, Houston's leading independent tenant and buyer representation firm, has announced the launch of its Healthcare Division with the appointment of Nelson Udstuen as President, Healthcare Division.